Grace Bird
Wellington Management Company
11 Papers
4 Citations
Grace Bird is an academic researcher from Wellington Management Company. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 2, co-authored 11 publications. Previous affiliations of Grace Bird include Victoria University of Wellington.
Chat about Author
Papers
Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology.
TL;DR: Asthma guidelines and clinician prescribing practice need to be modified in accordance with the currently available evidence of the dose-response relationship of ICS in adult asthma.
113
The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity.
TL;DR: A paradigm shift in asthma management that addresses the paradoxes of SABA reliever therapy is required; consideration needs to be given to replacement of SA BA reliever with ICS/fast-onset β-agonist reliever therapy across the range of asthma severity.
32
Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.
Richard Beasley,Richard Beasley,James Harper,Grace Bird,Harriette Dunphy,Alex Semprini,Ian D. Pavord,Alberto Papi,Mark Weatherall,Mark Weatherall +9 more
TL;DR: The limited available evidence suggests that budesonid/formoterol reliever therapy has greater potency and efficacy than budesonide/ formoterol fixed dose maintenance plus SABA reliever therapy in reducing the risk of a severe exacerbation.
Audit of oxygen administration to achieve a target oxygen saturation range in acutely unwell medical patients.
James Harper,James Harper,Nethmi Kearns,Grace Bird,Grace Bird,Robert McLachlan,Allie Eathorne,Mark Weatherall,Richard Beasley,Richard Beasley +9 more
TL;DR: In this paper, the authors evaluated documentation of a target oxygen saturation (SpO2) range and ability to achieve this range in acutely unwell inpatients in a single-centre audit.
5
Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold.
Grace Bird,Irene Braithwaite,James Harper,Steven McKinstry,Iris Koorevaar,James Fingleton,Alex Semprini,Meik Dilcher,Lance C. Jennings,Mark Weatherall,Richard Beasley +10 more
TL;DR: This is a randomised, single-blind, parallel-group trial comparing rNHF to ‘sham’ rhinothermy in the treatment of common cold, and the hypothesis is that delivery of humidified air heated to 41°C at high flow, nasal high flow rhInothermy (rNHF), for 2 hours daily for five days is more effective in reducing common cold symptom severity and duration.
4